Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Romana, Segati"'
Autor:
Cristina Falci, Cristina Oliani, Yasmina Modena, Barbara Corso, Caterina Modonesi, Silvia Toso, Donatella Da Corte Z, Elisabetta Cretella, AnnaPaola Fraccon, Antonella Brunello, Romana Segati, Laura Bertolaso, Milena Gusella, Carmen Barile, Roberto Padrini, Felice Pasini, Giovanni De Rosa, Nadia Minicuci
Publikováno v:
Pharmacology Research & Perspectives
In previous studies, steady‐state Z‐endoxifen plasma concentrations (ENDOss) correlated with relapse‐free survival in women on tamoxifen (TAM) treatment for breast cancer. ENDOss also correlated significantly with CYP2D6 genotype (activity scor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81b87bb551da3ef263348583e31cb5fd
https://pubmed.ncbi.nlm.nih.gov/32813313
https://pubmed.ncbi.nlm.nih.gov/32813313
Autor:
Enzo Galligioni, Antonello Veccia, Orazio Caffo, Annamaria Fariello, Fable Zustovich, Teodoro Sava, Romana Segati, Cosimo Sacco, Evi Comploj
Publikováno v:
BJU International. 108:1825-1832
Study Type – Therapy (RCT) Level of Evidence 1b What’s known on the subject? and What does the study add? Data on quality of life during docetaxel treatment in castration resistant prostate cancer was mainly provided by SWOG and TAX327 trials. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::607abc53c7301e3a86e30df240e49dac
https://doi.org/10.1111/j.1464-410x.2011.10277.x
https://doi.org/10.1111/j.1464-410x.2011.10277.x
Autor:
Orazio Caffo, Cosimo Sacco, Enzo Galligioni, Fable Zustovich, Annamaria Fariello, Teodoro Sava, F. Valduga, Evi Comploj, Gianluigi Cetto, Romana Segati
Publikováno v:
BJU International. 102:1080-1085
OBJECTIVE To report the results of a randomized phase II trial of docetaxel with and without estramustine phosphate (EP) in patients with hormone-refractory prostate cancer (HRPC). PATIENTS AND METHODS Patients with progressive HRPC were randomized t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee0eff3c3214ec6cb9a6df51f585499b
https://doi.org/10.1111/j.1464-410x.2008.07779.x
https://doi.org/10.1111/j.1464-410x.2008.07779.x
Autor:
Orazio, Caffo, Teodoro, Sava, Evi, Comploj, Annamaria, Fariello, Fable, Zustovich, Romana, Segati, Cosimo, Sacco, Antonello, Veccia, Enzo, Galligioni
Publikováno v:
BJU international. 108(11)
What's known on the subject? and What does the study add? Data on quality of life during docetaxel treatment in castration resistant prostate cancer was mainly provided by SWOG and TAX327 trials. In the TAX327 trial biochemical response and pain pred
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b0083ca00e5835058927a5f625ea6c6a
https://pubmed.ncbi.nlm.nih.gov/21615854
https://pubmed.ncbi.nlm.nih.gov/21615854
Autor:
Antonella Fede, L. Loreggian, Oscar Sala, Vanna Chiarion-Sileni, Romana Segati, Adriano Paccagnella, Mario V. Fiorentino, F. Calzavara, Adolfo Favaretto, Luigi Tomio, Pier Luigi Zorat, Francesco Francini, Claudio Andreoli, Ornella Lora, Maria Luisa Friso
Publikováno v:
Scopus-Elsevier
Europe PubMed Central
Europe PubMed Central
Cisplatin and 5-fluorouracil act as radiosensitizers and are active cytotoxic drugs in head and neck cancer. Therefore, from May 1987 to June 1990, we gave a continuous course of radiotherapy (70 Gy/35 fractions/7 weeks) combined with the simultaneou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3925e91b7a12d9d0bad1dfb555d02661
https://doi.org/10.1097/00000421-199306000-00014
https://doi.org/10.1097/00000421-199306000-00014
Autor:
Giovanni L. Pappagallo, Roberto Barbieri, Romana Segati, Franco Bassan, Orazio Caffo, Enzo Galligioni, L. Fratino, Antonello Veccia, Teodoro Sava, Emanuela Vaccher, Thomas Martini, Alessandra Perin
Publikováno v:
Urologic oncology. 31(2)
Objective Although there is no standard treatment after docetaxel failure in patients with castration-resistant prostate cancer (CRPC), second-line chemotherapy is increasingly required. Its mechanism of action and toxicity profile make pemetrexed su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fa20b1c967733f5ec7b6fd0070a7d96
https://pubmed.ncbi.nlm.nih.gov/21803618
https://pubmed.ncbi.nlm.nih.gov/21803618
Autor:
Teodoro Sava, Gianluigi Cetto, Maria Anna Giampaolo, Evi Comploj, Romana Segati, F. Valduga, Orazio Caffo, Enzo Galligioni
Objective Although docetaxel (DOC) plus prednisone is currently the treatment of choice for hormone-refractory prostate cancer (HRPC), no standard therapy is available for those patients who progress during DOC treatment. The aim of this study was to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f52a4ca5087b0ae7218035b8bfe4aed
http://hdl.handle.net/11562/344079
http://hdl.handle.net/11562/344079
Autor:
Matilde Pensabene, Carmela Pisano, Giuseppe Di Lorenzo, Giuseppe Castello, Pierluigi Bullian, Alessandro Ottaiano, Romana Segati, Guglielmo Nasti, Emiddio Barletta, Ernesto Mollo, Jane Bryce, Stefania Scala, Massimo Di Maio, Paolo A. Ascierto
Publikováno v:
Cancer immunology, immunotherapy : CII. 54(1)
Purpose: To review the content and quality of prospective clinical trials of biotherapies in solid tumors. Methods: Data were collected from the literature between 1990 and 2002 on general study characteristics, patient and disease factors, study met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e6228f1c074630c0b90e7750e8ceebd
https://pubmed.ncbi.nlm.nih.gov/15693138
https://pubmed.ncbi.nlm.nih.gov/15693138
Autor:
Giovanni Rosti, Anna Paola Fraccon, C. Abeni, D. Da Corte, M. Medici, Alessandra Bearz, Franco Bassan, F. Larussa, Donata Sartori, Francesco Grillone, Giovanni Vicario, G. Lo Re, Umberto Basso, Felice Pasini, Romana Segati, Cristina Pegoraro, F. Valduga, Carmen Barile, Caterina Modonesi, C. Graiff
Publikováno v:
Annals of Oncology. 25:iv291
line (ln) treatment (tx) was: sunitinib (su) 74%, sorafenib (so) 15.5%, temsirolimus (tem) 5%, others (5.5%). mOS was 26.7 for su, 21 for so (p= NS) and 4 for tem. Median 1 st ln PFS was 9.8 mo: su 12.3, so 7.2 (su vs so: p= 0.02), tem 1.9 (so vs tem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9395b526b3a4dd82407b5217f351c743
https://doi.org/10.1093/annonc/mdu337.31
https://doi.org/10.1093/annonc/mdu337.31
Autor:
Caterina Modonesi, Marta Zaninelli, Monica Ramello, Silvia Toso, Sabrina Carturan, Laura Bertolaso, Romana Segati, Marcello Magazu, Franco Bassan, Nadia Minicuci, Milena Gusella, Carmen Barile, Giorgio Crepaldi, Ottaviano Tomassi, Felice Pasini, Marta Mion, Anna Paola Fraccon, Robeto Padrini, Cristina Ghiotto, Anna Rizzi
Publikováno v:
Journal of Clinical Oncology. 31:e13514-e13514
e13514 Background: Endoxifen (EN), the main active metabolite of tamoxifen (T), reaches steady state (SS) plasma levels after about 4 months of administration. It derives principally by cytochrome CYP2D6 activity, which is highly variable among patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66c5e345eff99b1de6765fdd1654659b
https://doi.org/10.1200/jco.2013.31.15_suppl.e13514
https://doi.org/10.1200/jco.2013.31.15_suppl.e13514